6 results
To confirm the safety of the Articulinx ICC by evaluating device- and procedure relates adverse events.
Objectives of part A:- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after 5 days of dosing in people with Parkinson's disease- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after…
Our primary objective is to investigate whether noradrenaline exerts immunomodulatory effects in humans in vivo during experimental human endotoxemia. This will be determined by comparing plasma levels of various pro- and anti-inflammatory cytokines…
In a series of randomized control trials (RCTs) the following hypothesis will be tested: Intranasal administration of oxytocin and vasopressin affect neural and behavioral responses to infant signals and threat to the infant.* Oxytocin and…
Primary Objectives- To replicate AVP-induced inhibition of anterior cingulate cortex (ACC) activity and functional connectivity as measured by BOLD fMRI during a face matching task. - To assess the effect of RO5285119 in the modulation of AVP…
To examine the safety, tolerability, and pharmacokinetic profile of single ascending doses of AZ-009 compared to placebo (part B and C) or to Apo-Go (part A) in healthy volunteers being pretreated with domperidone and in patients with Parkinson…